Deals and Financings

• China's Chipscreen Bio traded 367% higher following its $148 million IPO on the Shanghai STAR exchange, raising its market cap to $4.2 billion; 
• Nanjing Frontier was approved to stage a $285 million IPO on the STAR Board to support its portfolio of long-acting drugs, including HIV treatments;
• Beijing Baicare Biotech closed a $9 million B financing for its automated clinical devices that detect pathogenic bacteria and antibiotic/drug resistance; 
• Stemirna Therapeutics, a Shanghai RNA biopharma, raised nearly $14 million in a Series A financing for its 12 mRNA drug projects; 
• Vapo Health, a China medical device company specializing in nebulizers, completed a "millions of dollars" Series A financing; 
• Qiyu Biotech, a Shanghai startup, completed a Series A round that raised "tens of millions of RMB" to develop large molecule candidates;

Trials and Approvals

• Aslan Pharma of Singapore started a major Phase Ib/II trial of varlitinib in patients with gastric cancer and a Phase II trial of ASLAN003 for advanced myeloid leukemia;
• DelMar Pharma of Vancouver reported positive results from its China Phase II trial of VAL-083 as a first line treatment for GBM; 
• Bio-Thera of Guangzhou began a China Phase I trial to examine BAT2506, a biosimilar to Janssen's arthritis treatment, Simponi®;
• Shanghai's Zai Lab announced its electric field treatment for cancer, Tumor Treating Fields, was designated an Innovative Medical Device in China.